Format

Send to

Choose Destination
Clin Genet. 2015 Sep;88(3):213-9. doi: 10.1111/cge.12536. Epub 2015 Jan 19.

Pancreatic cancer genomics: where can the science take us?

Graham JS1,2, Jamieson NB1,3,4, Rulach R2, Grimmond SM1,5, Chang DK1,6,7,8,9, Biankin AV1,6,7,8,9.

Author information

1
Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
2
Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
3
Academic Unit of Surgery, School of Medicine, College of Medical, Veterinary and Life Sciences, Glasgow, United Kingdom.
4
West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, University of Glasgow, Glasgow, United Kingdom.
5
Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
6
The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, University of New South Wales, Sydney, Australia.
7
Department of Surgery, Bankstown Hospital, Sydney, Australia.
8
St Vincent's Clinical School, Faculty of Medicine, Sydney, Australia.
9
South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia.

Abstract

The incidence of pancreatic ductal adenocarcinoma (PDAC) is steadily increasing and the annual death-to-incidence ratio approaches one. This is a figure that has not changed for several decades. Surgery remains the only chance of cure; however, only less than 20% of patients are amenable to operative resection. Despite successful surgical resection, the majority of the patients still succumb to recurrent metastatic disease. Therefore, there is an urgent need to develop novel therapeutic strategies and to better select patients for current therapies. In this review, we will discuss current management by highlighting the landmark clinical trials that have shaped current care. We will then discuss the challenges of therapeutic development using the current randomized-controlled trial paradigm when confronted with the molecular heterogeneity of PDAC. Finally, we will discuss strategies that may help to shape the management of PDAC in the near future.

KEYWORDS:

genomics; next-generation sequencing; pancreatic cancer; stratified medicine; translational medicine

PMID:
25388820
DOI:
10.1111/cge.12536
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center